Skip to main content
Edwards Lifesciences10-Q: Goodwill impairment

Edwards Lifesciences records $220.2 million impairment on in-process R&D intangible asset

Source: Autobound Signal API · 68 signals tracked for Edwards Lifesciences · updated

Get Edwards Lifesciences' live signals in Claude or ChatGPT, or by API

AskWhat changed at Edwards Lifesciences this week? Use Autobound signals for edwards.com.

What happened

Edwards Lifesciences recognized $220.2 million in intangible and long-lived asset impairment charges during the three and nine months ended September 30, 2026, primarily related to the full impairment of an in-process R&D asset. This write-down may lead management to reevaluate pipeline investments and seek external R&D partners or specialized clinical services.

Source

SEC EDGARNov 4, 2026

Quarterly report (Form 10-Q)

Edwards Lifesciences 10-Q for Quarter ended Sep 30, 2026

Filing excerpt

Intangible and long-lived assets impairment charges of $220.2 million during the three and nine months ended September 30, 2026 were primarily related to the full impairment of a certain in-process research and development asset.

sec.gov/Archives/edgar/data/1099800/000109980026000054/ew-20260930.htmRead the full source

Other signals in this filing (3)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Goodwill impairment

What this signalsFilings often name leadership changes, deals and spending plans.

Period
Quarter ended Sep 30, 2026
Fiscal year end
09/30
Filed
Nov 4, 2026

More 10-Q signals at other companies

The full record

From the Signal API record

Numbers

Dollar figure
$220M (impairment of a certain in-process research and development asset)

Details

CIK
1099800
Accession number
0001099800-26-000054
Timeframe
Current quarter
Quarter
Q3
Filing year
2026
Period end date
Sep 30, 2026
Why it matters
Strategic review underway
Signal category
Financial

Extraction

Confidence
High
Relevance
80%
Sentiment
Negative
Detected
Nov 10, 2026
signal_type
sec-10q
signal_subtype
goodwillImpairment

Use this data

Get every 10-Q signal for Edwards Lifesciences and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Edwards Lifesciences this week?”

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/9cdae906-6527-49e9-a3ac-75094e52ab54 returns this record as JSON. POST /v1/companies/enrich returns every signal for edwards.com.

{
  "signal_id": "9cdae906-6527-49e9-a3ac-75094e52ab54",
  "signal_type": "sec-10q",
  "signal_subtype": "goodwillImpairment",
  "detected_at": "2026-11-10T08:02:40.942+00:00",
  "company": {
    "name": "Edwards Lifesciences",
    "domain": "edwards.com"
  },
  "data": {
    "detail": "Edwards Lifesciences recognized $220.2 million in intangible and long-lived asset impairment charges during the three and nine months ended September 30, 2026, primarily related to the full impairment of an in-process R&D asset. This write-down may lead management to reevaluate pipeline investments and seek external R&D partners or specialized clinical services.",
    "metrics": {
      "timeframe": "current_quarter",
      "dollar_context": "impairment of a certain in-process research and development asset",
      "dollar_millions": 220.2
    },
    "quarter": "Q3",
    "summary": "Edwards Lifesciences records $220.2 million impairment on in-process R&D intangible asset",
    "excerpts": "Intangible and long-lived assets impairment charges of $220.2 million during the three and nine months ended September 30, 2026 were primarily related to the full impairment of a certain in-process research and development asset.",
    "relevance": 0.8,
    "sentiment": "negative",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/1099800/000109980026000054/ew-20260930.htm",
    "filing_date": "2026-11-04",
    "filing_year": 2026,
    "fiscal_year": 2026,
    "fiscal_year_end": "09/30",
    "period_end_date": "2026-09-30",
    "sales_relevance": "Strategic review underway",
    "signal_category": "financial"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.